SCHEMBL16398658

SCHEMBL16398658

O=Cc1cc(F)cc(-c2cccc(C(F)(F)F)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 2/20 0.41
FBP1 P09467 1/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PGR P06401 2/20 0.40
MAOB P27338 1/20 0.40
GALR1 P47211 1/20 0.40
KDM1A O60341 1/20 0.39
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
NR3C1 P04150 1/20 0.39
NOTUM Q6P988 2/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
PARP10 Q53GL7 1/20 0.38
PARP11 Q9NR21 1/20 0.38
IDO1 P14902 1/20 0.38
CES2 O00748 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18001843 0.88 RXRA (0.44) KIF11FBP1ALDH1A1POLBL3MBTL1
SCHEMBL18002151 0.85 RXRA (0.46) KIF11ALDH1A1POLBL3MBTL1PGR
SCHEMBL18001735 0.85 RXRA (0.43) KIF11PGRRXRARXRBRXRG
SCHEMBL18002087 0.83 PTPN5 (0.46) KIF11ALDH1A1POLBL3MBTL1PGR
SCHEMBL18003108 0.82 PTPN5 (0.47) KIF11ALDH1A1POLBL3MBTL1PGR
SCHEMBL18002313 0.82 RXRA (0.46) KIF11FBP1ALDH1A1POLBL3MBTL1
SCHEMBL7215429 0.80 KIF11 (0.56) KIF11ALDH1A1POLBL3MBTL1PGR
SCHEMBL1976815 0.80 TRIM24 (0.47) KIF11FBP1ALDH1A1POLBL3MBTL1
SCHEMBL30679628 0.80 KIF11 (0.56) KIF11ALDH1A1POLBL3MBTL1PGR
SCHEMBL18002212 0.80 L3MBTL1 (0.43) KIF11FBP1ALDH1A1POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 EP disclosed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed
EP-3022199-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2016-05-25 EP disclosed
WO-2015008872-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 KIF11 3245/4885FBP1 298/4885ALDH1A1 1611/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 KIF11 3245/4885FBP1 298/4885ALDH1A1 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.